Clover Biopharmaceuticals

Clover Biopharmaceuticals is a global clinical-stage biotechnology company developing transformative biologics as vaccines and therapeutics for the world’s most debilitating diseases. By leveraging its proprietary Trimer-Tag© platform, Clover has developed SCB-2019, a protein-based COVID-19 vaccine candidate. Clover expects to utilize its in-house cGMP biomanufacturing capabilities to potentially produce hundreds of millions of COVID-19 vaccine doses in 2021. Clover’s lead oncology asset, SCB-313, is in multiple ongoing Phase I clinical trials in Australia and China. Clover expects to advance multiple new pipeline products to the clinic in 2021 and continues to discover, develop and deliver innovative and affordable medical solutions to improve the quality of life and wellbeing of patients around the world. In just a few years, Clover has grown from less than 20 employees to a global R&D powerhouse with a diverse team of approximately 500 employees in China, U.S., UK, and Australia. Clover has corporate offices in Chengdu, Changxing, Shanghai and Beijing in China and expects to open a U.S. headquarters in Boston in the first half of 2021. Since 2020, Clover has raised more than USD $400 million and has built strong partnerships with internationally renowned healthcare organizations.